Pfizer Inc. — Sponsor Intelligence | 160 EU Trials

Filter these 160 trials by condition, phase, country and more.

Open in Search →

160 Registered trials

51 Recruiting

98 Completed trials

22 Countries active

148 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I (Other)

Phase III: 52 Phase II/III: 4 Phase II: 26 Phase I/II: 12 Phase IV: 7 Phase I: 13 Phase I (Other): 40 Phase I (FiH): 1 Other: 5

Oversight events:

1 serious breach 43 temporary halts 1 urgent safety measure 1 unexpected event 4 corrective measures across 17 trials

View oversight register →

100%

98 of 98 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 8 Alopecia areata 8 Migraine 6 Prostate cancer metastatic 6 Small cell lung cancer 4 Respiratory syncytial virus infection 4 Non-small cell lung cancer metastatic 4 Overweight 4 HER2 positive breast cancer 3 Colorectal cancer 3 Malignant melanoma 3 Obesity 3

Top IMPs

RITLECITINIB TOSILATE 10 PF-08634404 8 (3S)-3-[6-[4-[[1-[4-[(1R,2S)-6-HYDROXY-2-PHENYL-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL]PHENYL]PIPERIDIN-4-YL]METHYL]PIPERAZIN-1-YL]-3-OXO-1H-ISOINDOL-2-YL]PIPERIDINE-2,6-DIONE 6 ELRANATAMAB 6 PF-07220060 MONOHYDRATE 6 RIMEGEPANT 6 DEXAMETHASONE 4 ENZALUTAMIDE 4 HUMAN NORMAL IMMUNOGLOBULIN 4 PALBOCICLIB 4 5,8-DICHLORO-2-[(4-METHOXY-6-METHYL-2-OXO-1,2-DIHYDROPYRIDIN-3-YL)METHYL]-7-[(R)-METHOXY(OXETAN-3-YL)METHYL]-3,4-DIHYDROISOQUINOLIN-1(2H)-ONE 3 ABROCITINIB 3

All trials — page 7

160 total

A Phase 1 Study Evaluating Relative Bioavailability of Sprinkled Ritlecitinib in Applesauce, Yoghurt, and Strawberry Jam and Evaluating the … Ended

2022-502872-22-00 Phase I (Other) 1 country RITLECITINIB TOSILATE
C4951004 - BHV3000-406: A Phase 4, Randomized, Double-blind Placebo Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute … Ended

2024-513269-37-00 Phase IV 10 countries RIMEGEPANT
C4951012 - BHV3000-407: A Phase 4, Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Tolerability of Rimegepan… Ended

2024-513270-21-00 Phase IV 9 countries RIMEGEPANT
Phase 3, Placebo-Controlled, Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Trial of a 6-Valent OspA-Based Lyme Disease… Ended

2023-509105-72-00 Phase III 5 countries BORRELIA BURGDORFERI, SEROTYPE 1, OUTER SURFACE PROTEIN A FUSED VIA A LINKER TO …
PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCL… Ended

2024-511975-14-00 Phase I/II 5 countries CYCLOPHOSPHAMIDE MONOHYDRATE; IRINOTECAN HYDROCHLORIDE TRIHYDRATE; PALBOCICLIB; …
Clinical Outcomes, Tolerability and Safety of Oral Pantoprazole in Pediatric Participants Ended

2023-508770-28-00 Phase II 2 countries PANTOPRAZOLE SODIUM SESQUIHYDRATE
Single Dose Pharmacokinetics and Relative Bioavailability of Sayana Press via Upper Arm Injection Relative to Anterior Thigh and Abdomen Ended

2024-513561-39-00 Phase I (Other) 1 country
Long-Term PF-06651600 for the Treatment of Alopecia Areata (ALLEGROLT) Ended

2023-509801-59-00 Phase III 4 countries RITLECITINIB TOSILATE
A study comparing combination of Encorafenib + Binimetinib in Patients with BRAF V600-mutant Non-small Cell Lung Cancer. Ended

2024-515929-28-00 Phase II 3 countries BINIMETINIB; ENCORAFENIB
A study that allows patients from previous studies to continue on the medication. The aim of the study is to determine how safe and effectiv… Ended

2023-508955-37-00 Phase III 3 countries ABROCITINIB
A Long-Term, Open-Label, Study for Treatment of JIA Ended

2023-509651-14-00 Phase II/III 3 countries TOFACITINIB CITRATE
C4971006: A Study to Learn About the Effects of 2 Study Medicines (Maplirpacept [PF-07901801] and Glofitamab) When Given Together in People … Ended

2022-502822-41-00 Phase I/II 3 countries GLOFITAMAB; MAPLIRPACEPT; OBINUTUZUMAB
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan… Ended

2023-506487-13-00 Phase III 14 countries EVEROLIMUS; EXEMESTANE; FULVESTRANT; PF-07220060 MONOHYDRATE
A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called D… Ended

2024-513863-21-00 Phase I (Other) 1 country
C6081001: A Phase 1 Study of PF-07985045 in Participants with Advanced Solid Tumors Ended

2024-517988-23-00 Phase I 2 countries
A Study to Learn About the Study Medicine Called PF-07258669 in Older Adults Including Those at Risk of Malnutrition Ended

2025-520763-41-00 Phase I (Other) 1 country

Showing 145–160 of 160 trials

← All sponsors A–Z